The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics

Epilepsia

Volumn 39, Issue 12, 1998, Pages 1317-1323

  Mamiya, K ^a   Ieiri, I ^a   Shimamoto, J ^a   Yukawa, E ^a   Imai, J ^a   Ninomiya, H ^a   Yamada, H ^a   Otsubo, K ^a   Higuchi, S ^a   Tashiro, N ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP2C9; Genetic polymorphism; NONMEM; Phenytoin

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032440352     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01330.x     Document Type: Article

References (37)

1. 1 Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995 ; 36 (suppl 5): S8–13.
2. 2 Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996 ; 24: 1401–3.
3. 3 Fritz S, Lindner W, Roots I, Frey BM, Kiipfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987 ; 241: 615–22.
4. 4 Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′‐hydroxylation. Phumcol Ther 1990 ; 46: 341–7.
5. 5 Browne TR, LeDuc B. Phenytoin: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York Raven Press, 1995: 283–300.
6. 6 Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991 ; 31: 125–30.
7. 7 Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA‐expressed human liver cytochrome P450 2C9. Eiochem Biophys Res Commun 1991 ; 175: 1112–8.
8. 8 Veronese ME, Doecke CJ, Mackenzie PI, et al. Site‐directed mutation studies of human liver cytochrome P‐450 isozymes in the CYP2C subfamily. Biochem J 1993 ; 289: 533–8.
9. 9 Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4′‐hydroxylation of phenytoin: relationship to (9‐mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997 ; 43: 441–5.
10. 10 Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994 ; 4 285–99.
11. 11 Goldstein JA, Faletto MB, Romkes‐Sparks M, et al. Evidence hat CYP2C19 is the major (3‐mephenytoin 4′‐hydroxylase in humans. Biochemistry 1994 ; 33: 1743–52.
12. 12 Andersson T, Reghdh CG, Dahl‐Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S‐mephenytoin hydroxylators. Ther Drug Monit 1990 ; 12: 415–6.
13. 13 Bertilsson L, Henthom TK. Sanz E, Tybring G, Siwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S‐mephenytoin, but not to debrisoquin, hydioxylation phenotype. Clin Pharmacol Ther 1989 ; 45: 348–55.
14. 14 Ward SA, Helsby NA, Skjelbo E, Brfisen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism: a panel study. Br J Clin Pharmacol 1991 ; 31: 689–92.
15. 15 Skjelbo E, Brfisen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N demethylation of imipramine. Clin Pharmacol Ther 1991 ; 49: 18–23.
16. 16 de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S‐mephenytoin metabolism in humans. J Biol Chem 1994 ; 269: 15419–22.
17. 17 de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (5′)‐mephenytoin metabolism in Japanese. Mol Phannacol 1994 ; 46: 59–8.
18. 18 Scott J, Poffenburger PL. Pharmacogenetics of tolbutamide metabolism in human. Diabetes 1979 ; 28: 41–51.
19. 19 Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P450 2C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1992 ; 43: 234–9.
20. 20 Wang S‐L, Huang J‐D, Lai M‐D, Tsai J‐J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995 ; 5: 37–42.
21. 21 Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s. CYP2C19 and CYP2C9, in a Japanese population. 7'her Drug Monit 1998 ; 20: 243–7.
22. 22 Eto S, Noda H, Noda A. Simultaneous determination of antiepileptic drugs and their metabolites, including chiral compounds, via P‐cyclodextrin inclusion complexes by a column‐switching chromatographic technique. J Chromatogr B 1994 ; 658: 385–90.
23. 23 Beal SL, Sheiner LB, eds. NONMEM user's guide. San Francisco: NONMEM project group, University of California, 1992.
24. 24 Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chem Pharm Bull 1990 ; 38: 1973–6.
25. 25 Ieiri I, Goto W, Hirata K, et al. Effect of 5‐(p ‐hydroxyphenyl)‐5‐ phenylhydantoin P‐HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol 1995 ; 49: 51–6.
26. 26 Sullivan‐Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9‐Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 ; 6: 341–9.
27. 27 Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996 ; 6: 429–39.
28. 28 Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharrnacol Ther 1997 ; 62: 287–92.
29. 29 Ritte AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (s)‐warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994 ; 4: 3942.
30. 30 Furuya H, Fernandez‐Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995 ; 5: 3 89–92.
31. 31 Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997 ; 7: 361–7.
32. 32 Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC quantification of R‐ and S‐mephenytoin and comparison with the intron 4/EXOn 5 G + A‐splice site mutation. Pharmacogenetics 1995 ; 5: 80–8.
33. 33 Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19, in exon 5 and CYP2C19, in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996 ; 59: 647–53.
34. 34 Krecic ME, Shepard DR, Chang T‐H, Collins J, Gerber N. Stereoselective metabolism of phenytoin by hepatic microsomes and human CYP2C9 and CYP2C18 expressed in yeast. ISSX Proc 1995 ; 8: 370.
35. 35 Mamiya K, Ieiri I, Miyahara S, et al. Hydroxylation of phenytoin (PHT) and the cytochrome P450 (CYP) 2C subfamily. Epilepsia 1998 ; 39 (Suppl 5): S82–3.
36. 36 Mamiya K, Ieiri I, Miyahara S, et al. Association of polymorphisms in the cytochrome P450 (CUP) 2C19 and 2C18 genes in Japanese epileptic patients. Phamcogenetics 1998 887–90.
37. 37 Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997 ; 7: 405–9.